Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.85
Percentage change -2.63	%

Peers: BIIB REGN VRTX GILD NBIX ALNY PRTA ARWR SRPT FOLD

| Held by: VTI VB XBI VXF VBK ARKG IBB IWP SCHA IWF

Index	-	P/E	-	EPS (ttm)	-2.44	Insider Own	7.82%	Shs Outstand	157.81M	Perf Week	-6.07%
Market Cap	4.96B	Forward P/E	-	EPS next Y	-3.72	Insider Trans	-0.89%	Shs Float	145.55M	Perf Month	-17.51%
Income	-358.55M	PEG	-	EPS next Q	-1.11	Inst Own	99.20%	Short Float	7.49%	Perf Quarter	-19.74%
Sales	803.56M	P/S	6.18	EPS this Y	-36.81%	Inst Trans	9.45%	Short Ratio	7.61	Perf Half Y	-33.59%
Book/sh	4.20	P/B	7.49	EPS next Y	-6.16%	ROA	-11.92%	Short Interest	10.90M	Perf Year	-38.72%
Cash/sh	15.73	P/C	2.00	EPS next 5Y	-	ROE	-73.33%	52W Range	32.26 - 52.49	Perf YTD	-10.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-13.78%	52W High	-40.12%	Beta	0.35
Dividend TTM	-	Quick Ratio	8.82	Sales past 5Y	-4.33%	Gross Margin	95.93%	52W Low	-2.57%	ATR (14)	1.40
Dividend Ex-Date	-	Current Ratio	8.91	EPS Y/Y TTM	14.63%	Oper. Margin	-46.08%	RSI (14)	33.19	Volatility	5.63% 3.77%
Employees	927	Debt/Eq	3.00	Sales Y/Y TTM	30.63%	Profit Margin	-44.62%	Recom	1.68	Target Price	60.75
Option/Short	Yes / Yes	LT Debt/Eq	2.93	EPS Q/Q	8.09%	Payout	-	Rel Volume	0.96	Prev Close	32.28
Sales Surprise	3.42%	EPS Surprise	15.61%	Sales Q/Q	-7.21%	Earnings	Nov 06 BMO	Avg Volume	1.43M	Price	31.43
SMA20	-9.28%	SMA50	-12.49%	SMA200	-23.69%	Trades		Volume	1,370,706	Change	-2.63%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$67 → $60
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$53 → $62
Jul-16-24	Resumed	Jefferies	Buy	$29 → $75
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform	$44
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$58
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy	$52 → $62
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral	$33 → $52
Sep-29-23	Initiated	Raymond James	Strong Buy	$63
Jul-31-23	Upgrade	Citigroup	Neutral → Buy	$36 → $60
Jun-07-23	Resumed	Piper Sandler	Overweight	$58
May-04-23	Upgrade	Citigroup	Sell → Neutral	$30 → $36
Mar-21-23	Initiated	Bernstein	Underperform	$31
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $40
Sep-09-22	Resumed	Morgan Stanley	Overweight	$57
Jul-18-22	Resumed	Oppenheimer	Outperform	$59
Mar-31-22	Resumed	Piper Sandler	Overweight	$54
Mar-01-22	Initiated	Guggenheim	Buy	$64
Mar-01-22	Initiated	Citigroup	Sell	$26
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform	$40 → $30
Dec-14-21	Upgrade	William Blair	Mkt Perform → Outperform

Show Previous Ratings

Jan-17-25 11:22AM	Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-15-25 09:17AM	Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034 (GlobeNewswire)
Jan-13-25 08:00AM	Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum (PR Newswire)
Jan-12-25 09:00PM	Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities (GlobeNewswire)
Jan-08-25 04:11PM	Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
07:44PM	Loading…
Dec-20-24 07:44PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
03:09PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
10:23AM	FDA approves Ionis TRYNGOLZA for FCS treatment (Pharmaceutical Technology)
07:24AM	FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood (Benzinga)
06:00AM	Ionis gets a milestone approval; Another top FDA official to step down (BioPharma Dive)
Dec-19-24 06:28PM	TRYNGOLZA (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet (PR Newswire)
Dec-11-24 09:55AM	How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% (Zacks)
Dec-08-24 05:55PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Dec-06-24 11:31AM	Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-05-24 07:35AM	Theratechnologies enters exclusive licensing agreement with Ionis (TipRanks)
12:00PM	Loading…
Nov-27-24 12:00PM	Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Nov-26-24 08:00AM	Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-21-24 05:22PM	Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-19-24 07:08PM	Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
Nov-18-24 09:35AM	Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks (Zacks)
Nov-07-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
05:15AM	Ionis announces design for Phase III trial of Angelman syndrome therapy (Clinical Trials Arena)
04:26AM	Q3 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:18AM	Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com)
Nov-06-24 09:45AM	Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? (Motley Fool)
09:30AM	Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics (Zacks)
08:10AM	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:07AM	Ionis Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:01AM	Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome (PR Newswire)
07:00AM	Ionis reports third quarter 2024 financial results (PR Newswire)
09:44AM	Loading…
Nov-04-24 09:44AM	Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE (PR Newswire)
09:16AM	Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Oct-30-24 10:01AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-23-24 07:05AM	Ionis to hold third quarter 2024 financial results webcast (PR Newswire)
Oct-22-24 07:41AM	EU CHMP recommends AstraZeneca and Ionis Wainzua for ATTRv-PN (Pharmaceutical Technology)
Oct-21-24 02:08AM	WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (PR Newswire)
Oct-09-24 04:11PM	Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds (Insider Monkey)
Oct-08-24 07:30AM	New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA (GlobeNewswire)
Oct-03-24 07:00AM	New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (PR Newswire)
Oct-01-24 06:59PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
07:00AM	Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease (PR Newswire)
Sep-12-24 01:01PM	The Brawl Taking Shape Over Pfizers Multibillion-Dollar Heart Monopoly (The Wall Street Journal)
Sep-09-24 09:10PM	Ionis announces pricing of $500.3 million public offering (PR Newswire) -12.29%
04:20PM	Ionis announces proposed public offering of common stock (PR Newswire)
Sep-04-24 08:00AM	Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations (GlobeNewswire)
07:30AM	Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA (GlobeNewswire)
Aug-28-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Aug-15-24 09:15AM	Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth? (Zacks)
Aug-13-24 07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 11:34PM	Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary (GuruFocus.com)
Aug-02-24 01:32PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:54AM	Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises (Zacks)
04:34AM	Q2 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 10:00AM	Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:20AM	Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Ionis Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports second quarter 2024 financial results (PR Newswire)
Jul-31-24 09:00AM	Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx System for Administration of nusinersen (PR Newswire)
Jul-25-24 10:02AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-23-24 09:53AM	Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study (Zacks)
07:03AM	Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug (Clinical Trials Arena)
Jul-22-24 04:27PM	Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong (Investor's Business Daily) +5.83%
08:14AM	Ionis plots next steps for Angelman drug Biogen passed on (BioPharma Dive)
07:00AM	Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome (PR Newswire)
Jul-19-24 09:56AM	Ionis (IONS) Completes Enrolment for Rare Disease Drug Study (Zacks)
08:24AM	Ionis to hold second quarter 2024 financial results webcast (PR Newswire)
06:32AM	Ionis completes subject enrolment in Alexander disease treatment trial (Clinical Trials Arena)
Jul-18-24 07:00AM	Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease (PR Newswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jul-08-24 07:05AM	Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome (PR Newswire)
Jun-26-24 12:56PM	FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen (Zacks)
Jun-25-24 06:55AM	Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed (PR Newswire) +5.19%
06:30AM	Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock? (Zacks)
Jun-19-24 12:11PM	Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug (Zacks)
Jun-18-24 07:00AM	Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema (PR Newswire)
Jun-17-24 04:09PM	Ionis to present at TD Cowen Genetic Medicines & RNA Summit (PR Newswire)
Jun-06-24 11:31AM	Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-24 12:25PM	Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder (Benzinga)
07:00AM	Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema (PR Newswire)
May-28-24 07:00AM	Ionis to hold donidalorsen Phase 3 data webcast (PR Newswire)
May-23-24 07:00AM	New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) (PR Newswire)
May-17-24 10:10AM	Ionis (IONS), Biogen Down on Ending Development of ALS Drug (Zacks)
May-16-24 12:46PM	Top Stock Movers Now: Walmart, Canada Goose, Deere, and More (Investopedia)
10:54AM	Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study (MT Newswires)
08:50AM	Biogen, Ionis to Cease BIIB105 ALS Investigational Drug Development Following Phase 1/2 Trial Results (MT Newswires)
08:05AM	Biogen, Ionis shelve ALS drug following study failure (BioPharma Dive)
07:51AM	REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug (Reuters)
07:37AM	Biogen, Ionis will discontinue development of their ALS drug (Reuters)
07:30AM	Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis (PR Newswire)
07:30AM	Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis (GlobeNewswire)
07:00AM	Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome (PR Newswire)
May-15-24 07:05AM	Ionis to host 2024 virtual Annual Meeting of Stockholders (PR Newswire)
May-13-24 07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 06:30AM	The 3 Most Undervalued Pharma Stocks to Buy in May 2024 (InvestorPlace)
May-08-24 03:15PM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:59AM	Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $82 From $85, Maintains Overweight Rating (MT Newswires)
10:39AM	Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss (Zacks)
05:20AM	Q1 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:40AM	Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ... (GuruFocus.com)
May-07-24 05:02PM	Ionis Pharmaceuticals Insider Sold Shares Worth $256,277, According to a Recent SEC Filing (MT Newswires)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
YANG MICHAEL J.	Director	Jan 15 '25	Option Exercise	0.00	1,931	0	1,931	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 15 '25	Option Exercise	0.00	49	0	206	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 15 '25	Option Exercise	0.00	19,111	0	52,824	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 16 '25	Sale	32.84	7,154	234,959	45,670	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 16 '25	Sale	32.70	22	719	184	Jan 17 07:41 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 15 '25	Option Exercise	0.00	17,372	0	65,031	Jan 17 07:41 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 16 '25	Sale	32.79	6,523	213,889	58,508	Jan 17 07:41 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 15 '25	Option Exercise	0.00	19,690	0	68,563	Jan 17 07:41 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 16 '25	Sale	32.83	7,360	241,629	61,203	Jan 17 07:41 PM
Monia Brett P	Chief Executive Officer	Jan 15 '25	Option Exercise	0.00	73,448	0	240,841	Jan 17 07:41 PM
Monia Brett P	Chief Executive Officer	Jan 16 '25	Sale	32.63	33,445	1,091,444	207,396	Jan 17 07:41 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 15 '25	Option Exercise	0.00	23,887	0	116,755	Jan 17 07:40 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 16 '25	Sale	32.81	8,870	290,989	107,885	Jan 17 07:40 PM
Geary Richard S	EVP, Chief Development Officer	Jan 15 '25	Option Exercise	0.00	18,901	0	103,735	Jan 17 07:40 PM
Geary Richard S	EVP, Chief Development Officer	Jan 16 '25	Sale	32.86	7,072	232,407	96,663	Jan 17 07:40 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 15 '25	Option Exercise	0.00	12,295	0	20,204	Jan 17 07:40 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 16 '25	Sale	32.78	4,267	139,855	15,937	Jan 17 07:40 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 15 '25	Option Exercise	0.00	14,283	0	60,451	Jan 17 07:40 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 16 '25	Sale	32.70	5,400	176,580	55,051	Jan 17 07:40 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 15 '25	Option Exercise	0.00	18,011	0	97,618	Jan 17 07:40 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 16 '25	Sale	32.90	6,752	222,114	90,866	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 15 '25	Option Exercise	0.00	2,460	0	4,100	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 15 '25	Option Exercise	0.00	8,787	0	28,418	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '25	Sale	32.70	3,401	111,213	25,017	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '25	Sale	32.70	1,029	33,648	3,071	Jan 17 07:40 PM
Swayze Eric	Officer	Jan 16 '25	Proposed Sale	32.70	7,154	233,936		Jan 16 07:31 PM
Schneider Eugene	Officer	Jan 16 '25	Proposed Sale	32.70	6,523	213,302		Jan 16 07:30 PM
O'NEIL PATRICK R.	Officer	Jan 16 '25	Proposed Sale	32.70	7,360	240,672		Jan 16 07:29 PM
Monia Brett P	Officer	Jan 16 '25	Proposed Sale	32.70	33,445	1,093,652		Jan 16 07:28 PM
HOUGEN ELIZABETH L	Officer	Jan 16 '25	Proposed Sale	32.70	8,870	290,049		Jan 16 07:25 PM
Geary Richard S	Officer	Jan 16 '25	Proposed Sale	32.70	7,072	231,254		Jan 16 07:23 PM
Devers Shannon L.	Officer	Jan 16 '25	Proposed Sale	32.70	4,267	139,531		Jan 16 07:22 PM
Birchler Brian	Officer	Jan 16 '25	Proposed Sale	32.70	5,400	176,580		Jan 16 07:21 PM
BENNETT C FRANK	Officer	Jan 16 '25	Proposed Sale	32.70	6,752	220,790		Jan 16 07:19 PM
Baroldi Joseph	Officer	Jan 16 '25	Proposed Sale	32.70	3,401	111,213		Jan 16 07:18 PM
Hayden Michael R	Director	Dec 23 '24	Buy	36.22	5,000	181,079	35,219	Dec 26 04:57 PM
Swayze Eric	EVP Research	Nov 12 '24	Sale	37.92	1,194	45,278	33,713	Nov 14 05:30 PM
Monia Brett P	Chief Executive Officer	Nov 12 '24	Sale	38.05	6,630	252,294	167,393	Nov 14 05:30 PM
LOSCALZO JOSEPH	Director	Nov 12 '24	Sale	37.86	13,508	511,426	32,251	Nov 14 05:30 PM
Monia Brett P	Officer	Nov 12 '24	Proposed Sale	38.89	6,629	257,774		Nov 12 04:17 PM
Swayze Eric	Officer	Nov 12 '24	Proposed Sale	38.88	1,194	46,422		Nov 12 04:16 PM
LOSCALZO JOSEPH	Officer	Nov 12 '24	Proposed Sale	38.88	13,508	525,152		Nov 12 04:15 PM
Swayze Eric	EVP Research	Oct 15 '24	Option Exercise	0.00	125	0	210	Oct 17 06:42 PM
Swayze Eric	EVP Research	Oct 16 '24	Sale	38.31	53	2,031	157	Oct 17 06:42 PM
Geary Richard S	EVP, Chief Development Officer	Aug 29 '24	Sale	49.63	331	16,428	84,823	Sep 03 07:18 PM
Geary Richard S	EVP, Chief Development Officer	Aug 28 '24	Sale	49.16	320	15,731	85,154	Sep 03 07:18 PM
Geary Richard S	EVP, Chief Development Officer	Aug 05 '24	Sale	48.00	2,430	116,640	85,508	Aug 06 05:27 PM
Geary Richard S	Executive Vice President, Chie	Aug 05 '24	Proposed Sale	49.13	3,128	153,678		Aug 05 04:11 PM
WENDER JOSEPH H	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	132,756	Jul 17 05:03 PM
PARSHALL B LYNNE	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	87,265	Jul 17 05:03 PM
LOSCALZO JOSEPH	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	45,759	Jul 17 05:03 PM
KLEIN JOSEPH III	Director	Jul 16 '24	Option Exercise	24.42	12,000	293,040	12,000	Jul 17 05:02 PM
KLEIN JOSEPH III	Director	Jul 16 '24	Sale	50.00	12,000	600,000	0	Jul 17 05:02 PM
HERMAN JOAN E	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	42,007	Jul 17 05:02 PM
Diaz Allene M.	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	17,353	Jul 17 05:02 PM
Diaz Allene M.	Director	Jul 16 '24	Sale	49.49	1,637	81,019	15,716	Jul 17 05:02 PM
BERTHELSEN SPENCER R	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	151,934	Jul 17 05:02 PM
BERTHELSEN SPENCER R	Director	Jun 17 '24	Option Exercise	35.53	16,000	568,480	163,257	Jun 20 05:52 PM
BERTHELSEN SPENCER R	Director	Jun 17 '24	Sale	40.29	16,000	644,640	147,257	Jun 20 05:52 PM
WENDER JOSEPH H	Director	May 09 '24	Option Exercise	35.53	16,000	568,480	128,079	May 13 05:25 PM
KLEIN JOSEPH III	Director	May 03 '24	Sale	42.71	6,000	256,277	0	May 07 04:55 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 15 '24	Option Exercise	0.00	10,838	0	23,637	Apr 17 05:19 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 16 '24	Sale	41.60	4,006	166,641	19,631	Apr 17 05:19 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 15 '24	Option Exercise	0.00	1,875	0	47,061	Apr 17 05:16 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 16 '24	Sale	41.66	905	37,698	46,156	Apr 17 05:16 PM
Monia Brett P	Chief Executive Officer	Feb 16 '24	Sale	44.49	387	17,219	173,751	Feb 16 07:47 PM
Swayze Eric	EVP Research	Jan 31 '24	Sale	52.00	10,773	560,196	32,516	Feb 02 07:55 PM
Swayze Eric	EVP Research	Feb 02 '24	Sale	49.56	1,907	94,513	34,324	Feb 02 07:55 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Feb 02 '24	Sale	49.59	2,071	102,701	49,812	Feb 02 07:55 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Feb 02 '24	Sale	49.67	1,961	97,410	48,661	Feb 02 07:55 PM
Monia Brett P	Chief Executive Officer	Feb 02 '24	Sale	49.37	23,501	1,160,303	174,138	Feb 02 07:55 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Feb 02 '24	Sale	49.54	2,125	105,272	92,905	Feb 02 07:55 PM
Geary Richard S	EVP, Chief Development Officer	Feb 02 '24	Sale	50.04	1,961	98,135	87,334	Feb 02 07:54 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Feb 02 '24	Sale	49.60	2,125	105,404	35,825	Feb 02 07:54 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Feb 02 '24	Sale	49.52	1,853	91,752	79,079	Feb 02 07:54 PM
Monia Brett P	Chief Executive Officer	Jan 25 '24	Sale	51.75	2,285	118,249	151,851	Jan 29 05:34 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 25 '24	Sale	51.75	6,450	333,788	46,802	Jan 29 05:34 PM

Dollar change +0.03
Percentage change 1.02	%

ABCL AbCellera Biologics Inc daily Stock Chart

Peers: REGN AMGN VRTX MRNA BNTX INCY ALNY NVAX IONS EXEL

| Held by: IBB SPDW IDNA GWX LRNZ AVUS AVSC BBC BIB IBBQ

Index	-	P/E	-	EPS (ttm)	-0.60	Insider Own	24.86%	Shs Outstand	295.16M	Perf Week	1.71%
Market Cap	877.24M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	0.00%	Shs Float	221.93M	Perf Month	3.85%
Income	-175.80M	PEG	-	EPS next Q	-0.13	Inst Own	34.56%	Short Float	7.47%	Perf Quarter	13.36%
Sales	32.96M	P/S	26.62	EPS this Y	-15.13%	Inst Trans	-9.95%	Short Ratio	6.05	Perf Half Y	-2.94%
Book/sh	3.65	P/B	0.81	EPS next Y	3.35%	ROA	-12.10%	Short Interest	16.57M	Perf Year	-43.64%
Cash/sh	2.26	P/C	1.31	EPS next 5Y	-	ROE	-15.55%	52W Range	2.34 - 5.62	Perf YTD	1.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-15.36%	52W High	-47.15%	Beta	0.40
Dividend TTM	-	Quick Ratio	9.34	Sales past 5Y	476.52%	Gross Margin	-179.73%	52W Low	27.19%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	9.34	EPS Y/Y TTM	-33.92%	Oper. Margin	-934.58%	RSI (14)	50.75	Volatility	7.26% 6.48%
Employees	586	Debt/Eq	0.07	Sales Y/Y TTM	-34.59%	Profit Margin	-533.32%	Recom	1.22	Target Price	12.14
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	-75.40%	Payout	-	Rel Volume	0.57	Prev Close	2.94
Sales Surprise	-15.26%	EPS Surprise	-36.66%	Sales Q/Q	-1.39%	Earnings	Nov 05 BMO	Avg Volume	2.74M	Price	2.97
SMA20	0.29%	SMA50	2.52%	SMA200	-3.97%	Trades		Volume	1,566,275	Change	1.02%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy	$9
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$6
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight	$20
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy	$30
Nov-16-22	Initiated	Truist	Buy	$29
Dec-21-21	Initiated	The Benchmark Company	Buy	$27
Nov-19-21	Initiated	Piper Sandler	Overweight	$33
Jan-05-21	Initiated	SVB Leerink	Outperform	$45
Jan-05-21	Initiated	Stifel	Buy	$59
Jan-05-21	Initiated	Credit Suisse	Outperform	$52
Jan-05-21	Initiated	BMO Capital Markets	Outperform	$48
Jan-05-21	Initiated	Berenberg	Buy	$53

Show Previous Ratings

Jan-17-25 07:53AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jan-15-25 10:47AM	AbbVie and Simcere Zaiming link to develop trispecific antibody (Pharmaceutical Technology) +6.86%
Jan-14-25 09:25AM	AbCellera expands collaboration with AbbVie (TipRanks) -7.67%
Jan-13-25 09:00AM	AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology (Business Wire)
Jan-07-25 09:11AM	Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts? (Insider Monkey)
04:05PM	Loading…
Nov-21-24 04:05PM	AbCellera to Present at Upcoming Investor Conferences in December and January (Business Wire)
Nov-07-24 10:05AM	AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 (Business Wire)
Nov-05-24 11:17AM	Q3 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -5.88%
02:11AM	AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Nov-04-24 11:00PM	AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript (Motley Fool) +5.86%
05:55PM	AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q3 2024 Business Results (Business Wire)
Nov-01-24 09:06AM	AbCellera Biologics Inc (ABCL) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-22-24 04:05PM	AbCellera to Present at Upcoming Investor Conferences in November 2024 (Business Wire)
Oct-16-24 08:58AM	Is AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest Upside Potential According to Analysts? (Insider Monkey)
09:00AM	Loading…
Oct-04-24 09:00AM	AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 (Business Wire)
Sep-26-24 04:05PM	AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 (Business Wire)
Sep-01-24 10:26PM	AbCellera Biologics Inc. (ABCL): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
04:05PM	AbCellera to Present at Upcoming Investor Conferences in September (Business Wire)
05:13AM	AbCellera Biologics Inc. (ABCL): A Top Contender Among Canadas Best Penny Stocks in 2024 (Insider Monkey)
Aug-07-24 12:45AM	AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript (Motley Fool) -7.72%
Aug-06-24 06:15PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q2 2024 Business Results (Business Wire)
Aug-01-24 06:32AM	AbCellera and Lilly broadens antibody discovery partnership (Pharmaceutical Technology) -6.44%
Jul-31-24 09:00AM	AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines (Business Wire)
Jul-21-24 05:37AM	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? (Motley Fool)
Jul-09-24 12:00PM	AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-25-24 04:05PM	AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jun-13-24 05:40AM	Down 57%, Is AbCellera Biologics a Buy on the Dip? (Motley Fool)
04:05PM	Loading…
May-28-24 04:05PM	AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 (Business Wire) +5.97%
May-13-24 06:00AM	3 Stock Gems Hiding in the Nasdaq (InvestorPlace)
May-08-24 11:03AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:01AM	Q1 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
04:30AM	AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript (Motley Fool)
May-07-24 08:57PM	ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:01PM	AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates (GuruFocus.com)
04:05PM	AbCellera Reports Q1 2024 Business Results (Business Wire)
May-01-24 09:00AM	AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies (Business Wire)
Apr-30-24 10:01AM	Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-08-24 12:05PM	AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 (Business Wire)
Apr-03-24 04:05PM	AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Mar-27-24 04:30PM	The 7 Best Penny Stocks to Buy in Q2 2024 (InvestorPlace)
Mar-26-24 05:25PM	Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks (Insider Monkey) -6.33%
Mar-19-24 04:05PM	AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 (Business Wire)
Mar-11-24 09:00AM	AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions (Business Wire)
Mar-05-24 04:30PM	AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 (Business Wire)
Feb-26-24 06:55AM	3 Highly Rated Biotech Stocks to Buy for 300% Gains (InvestorPlace)
Feb-23-24 04:30PM	AbCellera Announces Resignation of Board Member (Business Wire)
Feb-22-24 08:15PM	AbCellera to Present at Upcoming Investor Conferences in March (Business Wire)
Feb-21-24 09:22AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.42%
07:09AM	Q4 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 11:00PM	AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript (Motley Fool)
07:00PM	AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:57PM	AbCellera Biologics Inc (ABCL) Faces Net Loss in FY 2023 Amid Strategic Shifts (GuruFocus.com)
04:05PM	AbCellera Reports Full Year 2023 Business Results (Business Wire)
Jan-30-24 01:02PM	Baillie Gifford Adjusts Stake in AbCellera Biologics Inc (GuruFocus.com) -5.55%
Jan-23-24 04:05PM	AbCellera to Report Full Year 2023 Financial Results on February 20, 2024 (Business Wire)
Jan-15-24 09:30AM	3 Growth Stocks That Could Go Parabolic in 2024 (Motley Fool)
Jan-03-24 09:40AM	Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-20-23 04:05PM	AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 (Business Wire)
Dec-16-23 01:00PM	AI Meets Biotech: 3 Top Stocks Transforming Medical Science (InvestorPlace)
Dec-11-23 03:30PM	16 Best Penny Stocks To Buy For 2024 (Insider Monkey)
Nov-16-23 04:05PM	AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023 (Business Wire)
Nov-03-23 12:05PM	AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023 (Business Wire) +6.09%
10:51AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:42AM	Q3 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
05:55AM	Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress (GuruFocus.com)
05:30AM	AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-02-23 05:56PM	AbCellera Biologics Inc (ABCL) Reports Q3 2023 Earnings: Revenue Drops to $7 Million (GuruFocus.com) +7.52%
04:05PM	AbCellera Reports Q3 2023 Business Results (Business Wire)
Nov-01-23 04:05PM	Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology (GlobeNewswire)
Oct-31-23 04:05PM	AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023 (Business Wire)
Oct-26-23 10:02AM	Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to Decline (Zacks)
Oct-11-23 04:05PM	AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023 (Business Wire) -9.34%
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-27-23 09:00AM	AbCellera Announces Two T-Cell Engager Presentations at SITC 2023 (Business Wire)
Sep-20-23 05:02PM	AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron (Business Wire)
Sep-14-23 07:03PM	Insider Buying: Veronique Lecault Acquires 20,000 Shares of AbCellera Biologics Inc (GuruFocus.com)
Sep-13-23 09:00AM	AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology (Business Wire)
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey) -6.03%
07:37AM	10 Stocks That Could 10X Over the Next 10 Years (Insider Monkey)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-04-23 10:23AM	Q2 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -13.34%
01:00AM	AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript (Motley Fool)
Aug-03-23 05:35PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q2 2023 Business Results (Business Wire)
Jul-26-23 01:17PM	10 Best Canadian Stocks Under $10 (Insider Monkey)
Jul-25-23 09:55AM	Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect? (Zacks)
Jul-24-23 04:05PM	AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights Request for Rehearing (Business Wire)
Jul-08-23 08:43PM	Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom (InvestorPlace)
Jul-06-23 04:05PM	AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023 (Business Wire)
Jun-17-23 09:52AM	AbCellera Biologics Insiders Added US$4.2m Of Stock To Their Holdings \ (Simply Wall St.)
May-30-23 06:50AM	Daily Vickers Top Buyers & Sellers for 05/30/2023 (Argus Research)
May-29-23 04:05PM	AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023 (Business Wire)
May-27-23 08:43AM	Strong week for AbCellera Biologics (NASDAQ:ABCL) shareholders doesn't alleviate pain of one-year loss (Simply Wall St.)
May-24-23 02:32PM	UPDATE 1-AbCellera to make C$701 million co-investment in Canada (Reuters)
01:56PM	AbCellera to make C$701 million co-investment in Canada (Reuters)
01:30PM	These Small-Cap Biotech Stocks Have the Wind at Their Back (TheStreet.com)

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Veronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Open in Screener

ETNB

89bio Inc

Jan 17 • 04:00PM ET

6.31

Dollar change +0.22
Percentage change 3.53	%

Healthcare • Biotechnology • USA • NASD

Peers: AKRO MDGL VKTX GNFT CENTA CGEN NBIX GILD VYGR PRTA

| Held by: VTI IWM VXF XBI IWN IBB VTWO SCHA VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-2.91	Insider Own	4.21%	Shs Outstand	117.58M	Perf Week	-3.07%
Market Cap	741.94M	Forward P/E	-	EPS next Y	-2.93	Insider Trans	-0.28%	Shs Float	112.63M	Perf Month	-20.13%
Income	-288.96M	PEG	-	EPS next Q	-0.75	Inst Own	92.72%	Short Float	6.92%	Perf Quarter	-26.71%
Sales	0.00M	P/S	-	EPS this Y	-58.97%	Inst Trans	8.21%	Short Ratio	7.86	Perf Half Y	-24.25%
Book/sh	3.56	P/B	1.77	EPS next Y	7.73%	ROA	-62.93%	Short Interest	7.79M	Perf Year	-44.65%
Cash/sh	3.60	P/C	1.75	EPS next 5Y	-	ROE	-73.31%	52W Range	5.99 - 16.63	Perf YTD	-19.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.24%	ROI	-69.64%	52W High	-62.06%	Beta	1.05
Dividend TTM	-	Quick Ratio	11.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	5.42%	ATR (14)	0.47
Dividend Ex-Date	-	Current Ratio	11.65	EPS Y/Y TTM	-45.57%	Oper. Margin	-	RSI (14)	31.27	Volatility	6.17% 7.14%
Employees	70	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	30.86
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-206.05%	Payout	-	Rel Volume	1.88	Prev Close	6.09
Sales Surprise	-100.00%	EPS Surprise	-122.90%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	991.98K	Price	6.31
SMA20	-13.74%	SMA50	-22.25%	SMA200	-25.00%	Trades		Volume	1,862,817	Change	3.53%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Resumed	BofA Securities	Buy	$30
Jan-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$24 → $15
Oct-10-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-28-23	Initiated	UBS	Buy	$36
Jun-13-23	Initiated	Evercore ISI	Outperform	$49
May-12-22	Upgrade	Raymond James	Outperform → Strong Buy	$33 → $12
Dec-20-21	Initiated	H.C. Wainwright	Buy	$46
Oct-26-21	Resumed	Cantor Fitzgerald	Overweight	$49
Jul-29-21	Resumed	BTIG Research	Buy	$60
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$65 → $35
Apr-21-21	Initiated	Cantor Fitzgerald	Overweight	$58
Oct-19-20	Initiated	Raymond James	Strong Buy	$65
Sep-25-20	Upgrade	BofA Securities	Neutral → Buy	$37 → $43
Jul-31-20	Initiated	Piper Sandler	Overweight	$54
Jul-23-20	Initiated	BTIG Research	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$58
Dec-09-19	Initiated	SVB Leerink	Outperform
Dec-09-19	Initiated	RBC Capital Mkts	Outperform
Dec-09-19	Initiated	Oppenheimer	Outperform
Dec-09-19	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Jan-13-25 08:00AM	89bio Provides Business Update and Outlook for 2025 (GlobeNewswire)
Dec-19-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.62% +12.94%
Dec-04-24 01:02PM	Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-29-24 01:30PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 04:05PM	89bio to Participate in the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
08:05AM	Loading…
Nov-15-24 08:05AM	89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 (GlobeNewswire) -9.37%
Nov-12-24 11:58PM	89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.95%
04:01PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Nov-07-24 04:05PM	89bio Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Nov-05-24 04:05PM	89bio to Participate in the UBS Global Healthcare Conference (GlobeNewswire) +10.18%
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
Nov-01-24 04:08PM	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH (Investor's Business Daily) +17.48%
Oct-18-24 01:01AM	Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings (GuruFocus.com)
Oct-17-24 01:05PM	State Street Corp's Strategic Acquisition in 89bio Inc (GuruFocus.com)
Oct-15-24 08:30AM	89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting 2024 (GlobeNewswire)
04:05PM	Loading…
Oct-11-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-24 04:05PM	89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference (GlobeNewswire)
Sep-19-24 04:03PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-24 04:05PM	89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer (GlobeNewswire)
Sep-04-24 04:15PM	NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth (GlobeNewswire)
Aug-29-24 08:00AM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-24 08:00AM	89bio Appoints Francis Sarena as Chief Operating Officer (GlobeNewswire)
Aug-05-24 09:55PM	ETNB Stock Earnings: 89bio Beats EPS for Q2 2024 (InvestorPlace) -5.84% -5.36%
04:05PM	89bio Reports Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
08:00AM	89bio Appoints Charles McWherter, Ph.D., to its Board of Directors (GlobeNewswire)
Jul-12-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
May-22-24 04:05PM	89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress (GlobeNewswire) -8.40%
May-14-24 08:00AM	89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis (GlobeNewswire)
04:05PM	Loading…
May-10-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:16PM	89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials (GuruFocus.com)
May-09-24 10:54PM	ETNB Stock Earnings: 89bio Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 11:56PM	Jump on the Bandwagon, Says Bank of America About These 2 Stock Picks (TipRanks)
04:05PM	89bio to Participate in the BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-06-24 12:00PM	All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy (Zacks)
May-02-24 04:05PM	89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH (GlobeNewswire)
Apr-17-24 04:05PM	89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors (GlobeNewswire)
Apr-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-03-24 07:01PM	89bio Inc CEO Rohan Palekar Sells 52,718 Shares (GuruFocus.com)
Mar-27-24 08:00AM	89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal) -6.80%
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 08:00AM	89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis (GlobeNewswire)
Mar-08-24 04:05PM	89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-07-24 01:34PM	Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Crispin Odey, Glen Kacher, Julian Robertson, Nelson Peltz, Brevan Howard Asset Management, SLR Investment Corp. (SLRC), 89bio, Inc. (ETNB), and More (Insider Monkey) +7.34%
Mar-05-24 04:05PM	89bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire) -14.81%
09:55AM	Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade (Zacks)
09:30AM	89BIO (ETNB) Just Overtook the 200-Day Moving Average (Zacks)
Mar-04-24 04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily) +9.11%
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
Mar-02-24 04:31AM	89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ... (GuruFocus.com)
Feb-29-24 04:05PM	89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) +10.03%
Feb-22-24 03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-06-24 04:05PM	89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -17.04%
Feb-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 09:35AM	89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Jan-10-24 09:55AM	Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect? (Zacks)
Dec-19-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.71%
Dec-12-23 07:30AM	89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-07-23 07:00AM	89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-06-23 04:36PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-04-23 07:00AM	89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 (GlobeNewswire) +7.74%
Nov-27-23 08:00AM	89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)
Nov-21-23 04:01PM	89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference (GlobeNewswire)
Nov-12-23 12:15PM	89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 07:28AM	89bio Inc (ETNB) Reports Increased R&D and G&A Expenses in Q3 2023 (GuruFocus.com)
Nov-08-23 04:01PM	89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.27%
Oct-17-23 08:00AM	89bio to Participate in the H.C. Wainwright 7 Annual NASH Investor Conference (GlobeNewswire)
Oct-11-23 03:49AM	Texas Instruments margins in for a squeeze; Silk Road walloped: 5 big analyst cuts (Investing.com) -13.04%
Oct-10-23 04:13PM	Why Shares of 89bio Plummeted on Tuesday (Motley Fool) -37.06%
Oct-03-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-21-23 08:00AM	89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)
Sep-20-23 08:00AM	89bio to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -9.84%
Sep-05-23 08:00AM	89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 04:01PM	89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-12-23 04:30PM	89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-07-23 09:40AM	Are Medical Stocks Lagging 89BIO (ETNB) This Year? (Zacks)
08:00AM	Obesity Drugs Wont Starve These Other Potential Blockbusters (The Wall Street Journal)
Jun-24-23 05:05AM	89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine (GlobeNewswire)
05:01AM	Data from 89bios ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress (GlobeNewswire)
Jun-07-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023 (GlobeNewswire)
May-29-23 09:35AM	89BIO (ETNB) Just Overtook the 20-Day Moving Average (Zacks)
May-23-23 08:00AM	89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) (GlobeNewswire)
May-13-23 08:53AM	Institutional investors are 89bio, Inc.'s (NASDAQ:ETNB) biggest bettors and were rewarded after last week's US$90m market cap gain (Simply Wall St.)
May-05-23 09:55AM	Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know (Zacks)
May-04-23 04:05PM	89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 08:00AM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-29-23 08:25AM	3 Biotech Buyout Targets to Watch (Motley Fool)
Apr-13-23 09:55AM	Wall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High? (Zacks) +6.78%
09:40AM	Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-02-23 08:27AM	Independent Director Michael Hayden Just Bought 41% More Shares In 89bio, Inc. (NASDAQ:ETNB) (Simply Wall St.)
Mar-24-23 10:57AM	Why Shares of 89bio Soared This Week (Motley Fool)
07:00AM	89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock (GlobeNewswire)
Mar-22-23 04:16PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +25.16% +23.83%
04:09PM	Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up (Investor's Business Daily)
09:14AM	89bio Rockets 30% And Akero Dives On A Scorching Battle In Liver Disease (Investor's Business Daily)

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Le-Nguyen Quoc	See Remarks	Jan 15 '25	Sale	6.49	10,963	71,150	271,833	Jan 17 04:01 PM
QUOC LE-NGUYEN	Officer	Jan 15 '25	Proposed Sale	6.49	10,963	71,110		Jan 15 04:13 PM
PALEKAR ROHAN	Chief Executive Officer	Dec 06 '24	Buy	7.89	5,000	39,450	471,236	Dec 10 06:02 AM
McWherter Charles	Director	Dec 05 '24	Buy	8.00	10,000	80,000	10,000	Dec 09 06:01 AM
PALEKAR ROHAN	Chief Executive Officer	Nov 22 '24	Buy	8.35	10,000	83,500	466,236	Nov 25 06:05 AM
Le-Nguyen Quoc	See Remarks	Oct 30 '24	Sale	8.12	27,955	226,995	187,796	Nov 01 04:01 PM
QUOC LE-NGUYEN	Officer	Oct 30 '24	Proposed Sale	8.12	27,955	226,972		Oct 30 04:20 PM
PALEKAR ROHAN	Chief Executive Officer	Apr 01 '24	Option Exercise	1.93	25,000	48,250	511,889	Apr 03 04:01 PM
PALEKAR ROHAN	Chief Executive Officer	Apr 01 '24	Sale	10.91	52,718	575,153	459,171	Apr 03 04:01 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 04 '24	Buy	15.35	1,350,000	20,722,500	12,431,584	Mar 06 05:40 PM
PALEKAR ROHAN	Chief Executive Officer	Feb 26 '24	Sale	10.76	4,477	48,173	486,889	Feb 28 06:43 PM

IONS

Ionis Pharmaceuticals Inc

ABCL

AbCellera Biologics Inc

ETNB

89bio Inc

Upgrade your FINVIZ experience